top of page

Make Passive income in 2024.

with the future of healthcare

Unattended Treatments | Preset protocols | Proven Results 

 THE FX Series by Erchonia®

The world's first non-invasive laser FDA cleared to treat overall body nociceptive pain

In 1997 a great innovator told us to "Think Different"... We listened. With years of dedication, research, and countless clinical trials; Erchonia Corporation makes history yet again, with the first low level pain laser ever FDA market cleared to treat overall body chronic pain. This laser has changed the healthcare industry forever.

Discover the only laser on the market for the treatment of chronic low back pain. Our new FDA market cleared laser has been proven in double-blind, placebo-controlled, randomized, parallel group, multi-center clinical trial to effectively treat this painful condition. The participants of the FX 635 Clinical Trial showed a 58% pain reduction at 2 month follow-up evaluation. This trial went on to demonstrate that the FX 635 is successful in the treatment of chronic low back pain. The recent clearance of the FX 635 is groundbreaking for the pain management community and the war on opioids.

For patients and physicians looking for an opioid-free alternative to lower back pain treatment, low back pain laser therapy is proving to be to be a medical breakthrough with incredible results, no harmful side-effects and, most promising of all, no potential for addiction.

*Real (1) Treatment Challenges

Plantar Fasciitis Patient Reaction to First Erchonia Laser Therapy Treatment
Play Video
Home: Welcome
Home: Features
Home: Products






FX Comp 1_edited.jpg


The FX Series uses low-level laser technology and patented laser diode arms to precisely target chronic pain centers. It reduces inflammation while promoting bio-stimulation at a cellular level in the musculoskeletal point of the pain’s origination. Unlike other lasers that can be too strong and unreliable: produce unwanted heat — the FX is fully compliant with ISO 13485 Medical Device Quality and IEC 60825-1 Laser Safety.

Patients with chronic low back pain who choose FX treatment experience improved comfort and quality of life without the risks associated with the side effects of opioids and nonsteroidal anti-inflammatory drugs — or NSAIDs — that can cause ulcers, bleeding, kidney disease and heart attacks.


The selection of products manufactured by Erchonia Corporation are not only of the highest quality, but are proven through level (1), double-blind, placebo-controlled, randomized, parallel group, multi-center clinical trial (The Gold Standard for Medical Devices.) To ensure you and your patients find the results you’re looking for. With 25 years of laser research, advanced technologies and a highly qualified team, we guarantee complete satisfaction.

Featured Event

Laser Marketing & Business Accelerator Program

September 15-16 | Live Stream


We are excited to bring you this new 2-day seminar called “The Laser M.B.A. Program”, or the Laser Marketing & Business Accelerator Program. The purpose of this program would be to give practitioners an in-depth, hands-on training on the very best proven marketing and business practices and strategies. This would help to ensure that:

  • Doctors are provided with a clear and proven success path for their business

  • Doctors are able to see rapid return on investment with their laser purchases

  • Doctors get the very most out of their investment with Erchonia from a financial standpoint

  • Doctors are able to help serve more patients in their communities

But that's not all! By attending, you'll receive over $5,000 in value, including exclusive courses, templates, done-for-you marketing pieces, e-books, white-label content, and more! The Laser M.B.A Program is designed to provide you with hands-on training and practical tools that will transform your practice and elevate your success.

FX 635_Q6x0_0110_ErchoniaProductShoot204_CaRom (20).jpg

Sign Up &
Learn More
about Laser

Anchor 1

Sign Up & Learn More About Laser Therapy

Contact Us

Home: Contact
bottom of page